RecruitingPhase 4NCT07222072

Methadone to Reduce Chronic Opioid Use After Major Spine Surgery: The MEND Pilot Feasibility Study


Sponsor

The Cleveland Clinic

Enrollment

120 participants

Start Date

Nov 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The investigators propose a randomized, triple-blinded (patients, investigators, outcomes assessors), placebo-controlled pilot feasibility trial (Methadone to End Narcotic Dependence, MEND trial) to assess the feasibility and safety of postoperative oral methadone in patients undergoing spine surgery and collect preliminary data to inform a larger clinical trial that will test the opioid-sparing effects of methadone at 3 months after spine surgery.


Eligibility

Min Age: 18 YearsMax Age: 72 Years

Inclusion Criteria2

  • Adult ≥ 18 years of age
  • Scheduled for multilevel lumbar and/or thoracic spine fusion (primary or revision)

Exclusion Criteria5

  • <18 or >72 Years of age
  • Body Mass Index >40
  • Known allergy to methadone
  • Pregnant females
  • Non-English-speaking patients

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMethadone

Patients randomized to receive (blinded) methadone: 5 mg twice daily on postoperative (post-op) days 1 and 2 followed by 5 mg daily on postop days 3, 4, and 5.

DRUGPlacebo

Patients randomized to receive (blinded) placebo will receive placebo twice daily on day 1 and day 2 and once daily on day 3, 4 and 5. Patients taking preoperative opioids will return to baseline opioid schedule after surgery.


Locations(1)

Cleveland Clinic

Cleveland, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07222072


Related Trials